Bringing the very best science and medicine to our best equine friends
October 2017

Kindred Biosciences to Announce Third Quarter 2017 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Tuesday, November 7, 2017 SAN FRANCISCO, Oct. 11, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its third quarter 2017 financial results on November 7, 2017 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 99251467. The call …

Continue Reading

Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference

SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer, will participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference, being held on October 11, 2017 in New York City. The event will feature one-on-one meetings at which investors will have the opportunity to meet with management to discuss key therapeutic programs in development and upcoming milestones. About Kindred Biosciences Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of …

Continue Reading